正常眼压性青光眼补充烟酰胺的交叉安慰剂对照随机临床试验
53例接受降眼压治疗、未治疗眼压≤18 mm Hg的正常眼压性青光眼参与者纳入双盲安慰剂对照交叉随机临床试验,随机接受口服安慰剂或烟酰胺,每阶段12周(1 g/日6周,随后2 g/日6周)。12周后烟酰胺组明视负反应峰谷幅值及B波幅值变化显著大于安慰剂组,而视野指标变化无显著组间差异。
要点
- 烟酰胺组明视负反应峰谷幅值变化3.121±3.968 μV,安慰剂组0.996±4.190 μV(p=0.045)。
- 烟酰胺组B波幅值变化2.112±3.220 μV,安慰剂组0.305±3.279 μV(p=0.032)。
- 平均偏差、模式标准差及视野指数12周变化无显著组间差异。
核心结论
- 正常眼压性青光眼参与者口服烟酰胺补充可诱导视网膜功能改善,以明视负反应峰谷幅值和B波幅值衡量。
- 鉴于正常眼压性青光眼眼压较低、电生理活动相关性可能较弱且进展较高眼压性青光眼慢,需进一步长期研究明确烟酰胺在该人群中的作用。
研究设计与样本
- 双盲、安慰剂对照交叉随机临床试验,纳入53例未治疗眼压≤18 mm Hg的正常眼压性青光眼参与者。
- 参与者随机接受口服安慰剂或烟酰胺,随后交叉且无洗脱期;每种治疗给药12周(烟酰胺/安慰剂1 g/日共6周,随后2 g/日共6周)。
- 视网膜功能采用全视野视网膜电图与视野检查评估;试验注册号NCT06078605。
主要发现
- 12周后明视负反应峰谷幅值变化烟酰胺组3.121±3.968 μV vs 安慰剂组0.996±4.190 μV(p=0.045)。
- 12周后B波幅值变化烟酰胺组2.112±3.220 μV vs 安慰剂组0.305±3.279 μV(p=0.032)。
- 明视负反应峰谷幅值改善超过95%变异系数两倍者烟酰胺组占29.0%,安慰剂组占19.3%。
- 12周后平均偏差、模式标准差及视野指数的变化均无显著组间差异。
关键数值与推荐
- 口服烟酰胺方案:1 g/日共6周,随后2 g/日共6周,每阶段共12周。
- 纳入标准为正常眼压性青光眼且未治疗眼压≤18 mm Hg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步长期研究以明确烟酰胺在正常眼压性青光眼人群中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: The neuroprotective effect of nicotinamide (NAM) supplementation has been demonstrated in both animal models and clinical trials. We conducted a trial to assess whether oral NAM improves retinal function in normal-tension glaucoma (NTG) participants receiving intraocular pressure (IOP)-lowering therapy. METHODS: Fifty-three NTG participants (untreated IOP ≤18 mm Hg) were enrolled in a double-masked, placebo-controlled crossover randomised clinical trial. Participants were randomly assigned to receive either oral placebo or NAM, followed by crossover without a washout period. Each treatment was administered for 12 weeks (NAM/placebo 1 g/day for 6 weeks, then 2 g/day for the subsequent 6 weeks). Retinal function was evaluated using full-field electroretinography and visual field testing. RESULTS: After 12 weeks, the amplitude changes of the photopic negative response in peak-to-trough (PhNRPT) and the B-wave were significantly greater in the NAM group (3.121±3.968 and 2.112±3.220 μV, respectively) compared with the placebo group (0.996±4.190 and 0.305±3.279 μV, respectively; p=0.045 and p=0.032). PhNRPT improved beyond twice the 95% coefficient of variation in 29.0% of the NAM group and 19.3% of the placebo group. No significant intergroup differences were observed in changes in mean deviation, pattern SD or visual field index after 12 weeks. CONCLUSION: Oral NAM supplementation in NTG participants induced functional improvement, as measured by PhNRPT and B-wave amplitude. Given that NTG is characterised by lower IOP, which may show a weaker correlation with electrophysiological activity and a slower progression rate compared with high-tension glaucoma, further long-term studies are needed to clarify the effects of NAM in this population. TRIAL REGISTRATION NUMBER: NCT06078605.
引用
- Ha A, Kim YK, Lee CK, et al. Effects of nicotinamide supplementation in normal-tension glaucoma: a crossover placebo-controlled randomised clinical trial. Br J Ophthalmol. 2026. PMID: 41167798. doi:10.1136/bjo-2025-328096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。